Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder

BACKGROUND: BUP-XR (SUBLOCADE(®)) is the first buprenorphine extended-release subcutaneous injection approved in the USA for monthly treatment of moderate-to-severe opioid use disorder (OUD). Among patients with OUD, those who inject or use high doses of opioids likely require higher doses of bupren...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenwald, Mark K., Wiest, Katharina L., Haight, Barbara R., Laffont, Celine M., Zhao, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693082/
https://www.ncbi.nlm.nih.gov/pubmed/38042801
http://dx.doi.org/10.1186/s12954-023-00906-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693082/
https://www.ncbi.nlm.nih.gov/pubmed/38042801
http://dx.doi.org/10.1186/s12954-023-00906-7

Ejemplares similares